Sodium Benzoate vs Recombinant Bovine Growth Hormone: which is worse?

What is Sodium Benzoate?

Sodium benzoate is the sodium salt of benzoic acid (C7H5NaO2). In acidic foods and beverages, it converts to benzoic acid, which inhibits microbial growth. While benzoic acid occurs naturally in some fruits and spices at low levels, the commercial preservative is synthetically manufactured.

What is Recombinant Bovine Growth Hormone?

Recombinant bovine growth hormone (rBGH), also called recombinant bovine somatotropin (rBST), is a synthetically produced version of the naturally occurring cattle growth hormone, manufactured using genetically engineered E. coli bacteria. Injected into dairy cows, it increases milk production by 10-15%. It was FDA-approved in 1993 under the brand name Posilac (originally Monsanto, later Elanco).

Documented risks

Sodium Benzoate: Sodium benzoate's most significant documented concern is the benzene formation reaction. When sodium benzoate coexists with ascorbic acid (vitamin C) in acidic conditions, they react in the presence of metal ions (iron, copper) and UV light to produce benzene, an IARC Group 1 human carcinogen. FDA surveys in 2005-2007 found benzene exceeding the EPA drinking water standard (5 ppb) in 79 of 200 commercial beverages tested. This triggered voluntary reformulations across the beverage industry. The 2007 McCann et al. Lancet study showed that the combination of sodium benzoate with six artificial food dyes significantly increased hyperactivity in children — the effect was synergistic, with the combination producing greater behavioral effects than either ingredient alone. This finding led directly to the EU's mandatory warning label requirement for products combining sodium benzoate with specified dyes. A 2010 study in ADHD: Attention Deficit and Hyperactivity Disorders found associations between urinary sodium benzoate/hippuric acid metabolite levels and ADHD symptom severity in children, independent of dye exposure. A 2019 study in Nutrients (PMC6520673) found similar associations in Korean children. Mitochondrial DNA damage: Dr. Peter Piper at the University of Sheffield found that sodium benzoate at concentrations used in some beverages could damage mitochondrial DNA in yeast cells, potentially affecting mitochondrial function. These findings have not been fully replicated in human tissue studies. Hypersensitivity reactions including urticaria, angioedema, and contact dermatitis are documented. Cross-reactivity with aspirin has been reported in aspirin-sensitive individuals.

Recombinant Bovine Growth Hormone: The central human health concern is that rBGH treatment significantly elevates insulin-like growth factor 1 (IGF-1) levels in treated cows' milk. IGF-1 is a naturally occurring growth hormone that promotes cell growth and division. Multiple epidemiological studies have associated elevated blood IGF-1 levels with increased cancer risk in humans. A 1998 study in The Lancet (Hankinson et al.) found that women with the highest IGF-1 blood levels had approximately 7 times the breast cancer risk compared to those with the lowest levels. A 2004 meta-analysis in JNCI (the Journal of the National Cancer Institute) confirmed significant associations between high IGF-1 levels and breast, prostate, and colorectal cancer risk. The mechanistic question is whether consuming rBGH-treated milk raises blood IGF-1 levels in humans. The FDA and WHO/FAO Codex Alimentarius concluded that IGF-1 in milk is a protein largely digested in the GI tract before absorption. Canadian regulatory researchers challenged this, arguing that pasteurization reduces proteases that would otherwise break down IGF-1, potentially allowing more intact IGF-1 to survive digestion. The Codex Alimentarius Commission made history in 1999 by declining to endorse rBST safety maximum residue limits — a split vote (33 in favor of the MRL, 29 against, with abstentions) demonstrating fundamental international disagreement. This is one of very few cases where Codex failed to establish a safety standard. Animal welfare is a second major concern: Health Canada's comprehensive 1999 review found that rBGH-treated cows had 25% higher rates of clinical mastitis, 50% higher lameness risk, increased reproductive problems, and shortened productive lifespans, requiring substantially more antibiotic treatment — an antibiotic resistance concern. Canada rejected rBGH approval in 1999 after its scientific review; the EU banned it in 1999.